A Randomized, Double-blind, Placebo-controlled, Single Ascending Doses (SAD) Study Following Oral Administration in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of HNC1058
Latest Information Update: 26 Mar 2024
At a glance
- Drugs HNC-1058 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; First in man
- Sponsors Guangzhou Henovcom Bioscience
Most Recent Events
- 19 Mar 2024 Status changed from recruiting to completed.
- 02 Jan 2024 Planned End Date changed from 18 Sep 2023 to 27 Mar 2024.
- 02 Jan 2024 Planned primary completion date changed from 18 Aug 2023 to 27 Mar 2024.